41 Specifically, rs7242481, located in the 5 untranslated region (UTR) of SLC39A6 , disturbs a transcriptional repressor binding site and results in the upregulation of SLC39A6 expression
In separate Phase 2 and Phase 3 trials, retatrutide at 12mg produced greater total body weight reduction than semaglutide at 2.4mg across comparable timeframes, with the difference primarily attributable to retatrutides additional glucagon receptor activation
Key Background A study published by the American Diabetes Association earlier this yearinvolving more than 47,000 participants with type two diabetesindicated an increased risk of all thyroid cancer and medullary thyroid cancer after using GLP-1 drugs
Tsai WH, Sung FC, Chiu LT, Shih YH, Tsai MC, Wu SI